QIAGEN enhances bioinformatics portfolio with acquisition of OmicSoft

11-Jan-2017 - Germany

Qiagen announced the acquisition of OmicSoft Corporation, providing access to OmicSoft’s powerful multi-omics data management infrastructure solution as well as expertly curated ‘omics’ data sets that complement QIAGEN’s bioinformatics portfolio that are relied upon by customers worldwide to gain valuable insights into complex biological data.

OmicSoft is recognized for its suite of software solutions that enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets – such as The Cancer Genome Atlas (TCGA) operated by the U.S. National Cancer Institute – and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.

OmicSoft is expected to greatly enhance QIAGEN’s industry-leading bioinformatics portfolio by adding key features for the management, analysis and sharing of both primary data and analyzed results, while also expanding the range of QIAGEN’s translational and clinical applications.

Thermo Fisher Scientific to Acquire QIAGEN

Read news

Through the addition of OmicSoft, QIAGEN will now offer solutions across the full spectrum of data management and interpretation needs. Within these infrastructure solutions, OmicSoft adds the ability to mine curated ‘omics’ data for unpublished findings. QIAGEN will be able to offer:

Literature-based interpretation: QIAGEN is the leader in intuitive web-based applications to analyze and interpret the biological meaning of genomic data using rich content from millions of curated articles from scientific and medical literature. The foundation is the Ingenuity Knowledge Base and interpretation tools such as IPA and QIAGEN Clinical Insight (QCI).
Intra-institution and inter-institution data management, analysis, sharing and interpretation solutions for data created or owned by a customer as well as for OmicSoft’s curated data sets.

In addition, OmicSoft brings to QIAGEN scalable and flexible software architecture solutions that will enable efficient future expansion of QIAGEN’s bioinformatics offerings.

“The addition of OmicSoft to QIAGEN’s portfolio of Sample to Insight solutions reinforces our position as the gold standard for analysis and interpretation of complex biological data across many different disciplines,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

“The OmicSoft team has deep expertise that will enable QIAGEN to better support customers in managing vast data sets and gaining actionable insights for discovery and translational research,” said Dr. Laura Furmanski, Senior Vice President and Head of the Bioinformatics Business Area at QIAGEN. “The market opportunity is significant given the expanding use of multiple ‘omics’ data in research and clinical healthcare. We intend to integrate the OmicSoft solutions into our full bioinformatics interpretation portfolio, and make it a key differentiator in our Sample to Insight offerings.”

OmicSoft offers a portfolio of solutions that collects, curates and standardizes massive amounts of public research data to enable customers to access findings through a single multi-omics platform. Three major solutions combine content with software in the user-friendly Array Suite:

Land technology – collecting and managing large public data sets in curated knowledge bases in fields such as cancer genomics (OncoLand), cardiovascular, metabolic and immunology (DiseaseLand), and genetic research (GeneticsLand).
Array Server software – providing the enterprise back-end solution for project management, sample management, data storage and access to the Land databases.
Array Studio software – providing a graphical user interface to browse, analyze and visualize data from NGS sequencing, microarray and other technologies.

OmicSoft will operate as a QIAGEN company from its headquarters in the Research Triangle region. Dr. Jack Liu, Co-Founder and President, will remain with QIAGEN to lead future product development of the OmicSoft portfolio.

https://www.bionity.com/en/news/161317/qiagen-enhances-bioinformatics-portfolio-with-acquisition-of-omicsoft.html